Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 367, Issue 2, pp 134–139 | Cite as

Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine

  • J. Peinado
  • A. Hameg
  • R. P. GarayEmail author
  • F. Bayle
  • P. Nuss
  • M. Dib
Original Article


The low incidence of extrapyramidal effects with atypical neuroleptics has been ascribed to their 5-HT2A- and 5-HT2C-serotonin receptor antagonistic properties. On the other hand, the acute increase in striatal dopamine release by submaximal dopamine D2 autoreceptor blockade can be respectively reduced and increased by 5-HT2A- and 5-HT2C-antagonists. Cyamemazine is a neuroleptic D2- and 5-HT2A-receptor antagonist, with small antagonistic activity at 5-HT2C receptors and low incidence of extrapyramidal side effects. Therefore, submaximal cyamemazine was tested in rats for its acute action on the extracellular concentrations of dopamine and dopamine metabolites (DOPAC: 3,4,dihydroxyphenylacetic acid and HVA: 4-hydroxy-3-methoxy-phenyl-acetic acid) in the corpus striatum. The serotonin metabolite 5-HIAA (5-hydroxy-indole-acetic acid) was measured in parallel. Rats prepared for microdialysis (striatum) were intraperitoneally given cyamemazine 1 mg/kg, 5 mg/kg or vehicle (n=4 in each group). Dopamine, DOPAC, HVA and 5-HIAA concentrations in perfusates under basal conditions and after stimulation by high K+ were measured by HPLC coupled to electrochemical detection. Cyamemazine 1 mg/kg significantly reduced extracellular concentrations of basal dopamine (−77%), DOPAC (−54%), HVA (−54%) and 5-HIAA (−65%). No such effects were seen with the dose of cyamemazine 5 mg/kg or for K+-evoked dopamine release. In conclusion, submaximal cyamemazine can acutely reduce basal dopamine release and metabolism in the rat striatum. Such unusual action can be explained by the original pharmacological profile of cyamemazine (potent D2- and 5-HT2A-antagonist, with small antagonistic activity at 5-HT2C receptors). Further experiments are required to explain the low incidence of extrapyramidal side actions with cyamemazine.


Cyamemazine Microdialysis Dopamine Serotonin Striatum Rat 



We are greatly indebted to E. Garay (Pharmalex s.a., Paris, France), who helped with the coordination and monitoring of this study.


  1. Alcantara AG, Barcia D (1999) Risperidone and concept of bipolar neuroleptic. Encephale 25:146–150PubMedGoogle Scholar
  2. Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (2000) 5-HT3- and 5-HT2C-receptor antagonist properties of cyamemazine: significance for its clinical anxiolytic activity. Psychopharmacology 147:412–417Google Scholar
  3. Alvarez-Guerra M, Hameg A, Dib M, Garay RP (2002) 5-HT2A-receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 454:235–239Google Scholar
  4. Bhana N, Foster RH, Olney R, Plosker GL (2001) Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111–161PubMedGoogle Scholar
  5. Bourin M, Dhonnchadha BAN, Colombel MC, Dib M, Hascoët M (2001) Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 124:87–95CrossRefPubMedGoogle Scholar
  6. De Klippel N, Sarre S, Ebinger G, Michotte Y (1993) Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 630:57–64PubMedGoogle Scholar
  7. Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001) Role of 5-HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229–232PubMedGoogle Scholar
  8. Di Matteo V, Cacchio M, Di Giulio C, Di Giovanni G, Esposito E (2002) Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5)HT(2C) receptors in vivo. Pharmacol Biochem Behav 71:607–613CrossRefPubMedGoogle Scholar
  9. Dubroca JM (1989) L'anxiolyse: intérêt de la cyamémazine. Neuro-Psy :4–7Google Scholar
  10. Dyr W, Kostowski W (1997) Effects of 5-HT3 receptor agonists on voluntary ethanol intake in rats maintained on a limited access procedure. Alcool 32:455–462Google Scholar
  11. Garay RP, d'Alché-Birée F (1995) Cyamémazine (Tercian®): profil neuroleptique ou anxiolytique ?. Inf Psychiatr 10:969–970Google Scholar
  12. Hernandez L, Hoebel BG (1995) Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats. Pharmacol Biochem Behav 52:581–589CrossRefPubMedGoogle Scholar
  13. Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors. J Pharmacol Exp Ther 295:226–232PubMedGoogle Scholar
  14. Ichikawa J, Meltzer HY (1995) DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 698:204–208CrossRefPubMedGoogle Scholar
  15. Invernizzi R, Pozzi L, Samanin R (1995) Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 34:211–215CrossRefPubMedGoogle Scholar
  16. Julou L, Ducrot R, Fournel J, Leau O, Bardone MC, Myon J (1961) Etude des propriétés pharmacologiques de la cyano-3 (diméthyl-3' méthyl-2 propyl)-10 phénotiazine ou cyamépromazine (7.204 R.P.) Comptes Rendus Soc Biol 155:1029–1034Google Scholar
  17. Lidow MS, Goldman-Rakic PS (1997) Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939–946PubMedGoogle Scholar
  18. Lucas G, De Deurwaerdère, Caccia S, Spampinato U (2000) The effect of serotoninergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39:1053–1063Google Scholar
  19. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 [Suppl 2]:106S–115SGoogle Scholar
  20. Ng NK, Lee HS, Wong PT (1999) Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 55:600–607CrossRefPubMedGoogle Scholar
  21. Pehek EA, Yamamoto BK (1994) Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63:2118–2124PubMedGoogle Scholar
  22. Radat F (1995) Cyamémazine: traitement symptomatique des dimensions anxieuses, impulsives et agressives. Inf Psychiatr 10:967–968Google Scholar
  23. Sibley DR (1999) New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 39:313–341CrossRefPubMedGoogle Scholar
  24. Sotnikova TD, Gainetdinov RR, Grekhova TV, Rayevsky KS (2001) Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum. Pharmacol Res 43:283–290Google Scholar
  25. Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989PubMedGoogle Scholar
  26. Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119–133PubMedGoogle Scholar
  27. Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur J Pharmacol 242:151–163CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • J. Peinado
    • 1
  • A. Hameg
    • 2
  • R. P. Garay
    • 3
    Email author
  • F. Bayle
    • 4
  • P. Nuss
    • 5
  • M. Dib
    • 2
  1. 1.School of MedicineUniversity of GrenadeGrenadeSpain
  2. 2.AventisParisFrance
  3. 3.INSERM U400Faculté de Médecine de CréteilCréteil CédexFrance
  4. 4.Inserm EMI-E0117Université Paris VParisFrance
  5. 5.Hôpital Saint-AntoineParisFrance

Personalised recommendations